Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.
Cipla Ltd.’s admitted its smaller presence in the US compared with certain Indian peers may be dragging down its earnings, but expects its recent acquisition there, a ramp up in product filings and new product roll-outs to change things.
At the firm's 80th annual general meeting in Mumbai, Cipla's managing director and global CEO, Umang Vohra, said that the...
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
